Web: | mayocliniclabs.com |
---|---|
Email: | mcl@mayo.edu |
Telephone: | 800-533-1710 |
International: | +1 855-379-3115 |
Values are valid only on day of printing. |
Identifying individuals who are at increased risk of adverse drug reactions with drugs that are metabolized by UGT1A1, including irinotecan, atazanavir, nilotinib, pazopanib, and belinostat
Identifying individuals who are at risk of hyperbilirubinemia
Follow-up testing for individuals with a suspected UGT1A1 variant, who had negative TA repeat region testing
Establishing a diagnosis of Gilbert, Crigler-Najjar syndrome type I or type II
Establishing carrier status for Gilbert, Crigler-Najjar syndrome type I or type II
This is a full gene sequencing test for UGT1A1 that includes the TA repeat region of the promoter and all intron/exon boundaries. Results are interpreted for the purposes of UGT1A1 drug metabolism and hereditary hyperbilirubinemia syndromes (Gilbert syndrome and Crigler-Najjar syndrome).
This test screens for UGT1A1 gene variants associated with increased risk of adverse drug reactions when taking UGT1A1-metabolized drugs. These drugs include irinotecan, atazanavir, nilotinib, pazopanib, and belinostat
This test screens for UGT1A1 gene variants associated with congenital hyperbilirubinemia conditions including Gilbert syndrome, Crigler-Najjar syndrome type I and type II
See UGT1A1 Test-Ordering Algorithm in Special Instructions.
Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis